Chinese phase 2 trial finds COVID-19 vaccine is safe and induces an immune response

A phase 2 randomized controlled trial of a recombinant adenovirus type-5-vectored COVID-19 vaccine (Ad5-vectored COVID-19 vaccine) was conducted in China in April 2020 and involved more than 500 people. The primary objective of the study was to evaluate the immune response and safety of the vaccine, and to determine the most suitable dose for a phase 3 trial. Phase 3 trials are needed to confirm whether the vaccine candidate effectively protects against SARS-CoV-2 infection.

About admin

Now Dr. Jack Straw is in charge of the website, and organizes it so that medical care is available to everyone. In addition, he is an active member of the medical community, regularly attending international conferences and sharing his experience and knowledge. Dr. Straw is not only a medical professional and website manager, but also a loving husband and father of his beautiful children.
View all posts by admin →

Leave a Reply

Your email address will not be published. Required fields are marked *